✦ LIBER ✦

PND1 A Risk-Benefit Analysis of Natalizumab Across PML Risk Sub-Groups in Patients With Relapsing-Remitting Multiple Sclerosis

✍ Scribed by A.R. Walker; B. Deniz; S.T. Alexopoulos; R. Arnold; D. Bates

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND1 ASSESSING THE NET CLINICAL BENEFIT

✍ A AL-Sabbagh; R Bennett; R Glanzman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

PND1 Estimating Net Health Benefits Of I

✍ S.M. Szabo; C. Dembek; P. Moore; L.A. White; H. Wijaya; A.R. Levy 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PND13 A COST-EFFECTIVENESS ANALYSIS OF N

✍ R Gani; ER Samuels; S Hughes; G Giovanonni 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB